Soleno Therapeutics, Inc. (SLNO) Stock Analysis

Soleno Therapeutics (SLNO) Surges Nearly 60% In April Amid Neurocrine Acquisition Deal

Fri, May 1, 2026 at 2:46 PM UTC 3 min read

Soleno Therapeutics (SLNO) experienced a nearly 60% surge in April following the announcement of an acquisition deal by Neurocrine Biosciences. This significant price increase reflects investor optimism regarding the potential for enhanced growth and development opportunities for Soleno’s product pipeline under Neurocrine's resources. The acquisition could lead to increased market presence and financial stability, making SLNO a more attractive investment in the biotech sector.

Read full article →

Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why

Wed, April 8, 2026 at 3:23 PM UTC 3 min read

Soleno Therapeutics' stock surged 56.4% over the past week, driven by positive developments regarding its lead drug candidate, DCCR, for the treatment of Prader-Willi syndrome. This significant rally reflects growing investor confidence in the company's potential to secure regulatory approval and commercial success. As the market responds to these advancements, investors may see this as an opportunity for potential gains in the biotech sector.

Read full article →